Flurbiprofen axetil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Flurbiprofen axetil
Accession Number
DB14938
Type
Small Molecule
Groups
Investigational
Description

Flurbiprofen axetil is under investigation in clinical trial NCT02043366 (Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients).

Structure
Thumb
Synonyms
Not Available
Categories
UNII
I0OU31PUI5
CAS number
91503-79-6
Weight
Average: 330.355
Monoisotopic: 330.126737255
Chemical Formula
C19H19FO4
InChI Key
ALIVXCSEERJYHU-UHFFFAOYSA-N
InChI
InChI=1S/C19H19FO4/c1-12(19(22)24-14(3)23-13(2)21)16-9-10-17(18(20)11-16)15-7-5-4-6-8-15/h4-12,14H,1-3H3
IUPAC Name
1-(acetyloxy)ethyl 2-{2-fluoro-[1,1'-biphenyl]-4-yl}propanoate
SMILES
CC(OC(C)=O)OC(=O)C(C)C1=CC(F)=C(C=C1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with 4-hydroxycoumarin.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Abciximab.
AcebutololFlurbiprofen axetil may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Flurbiprofen axetil.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Flurbiprofen axetil.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Acenocoumarol.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Flurbiprofen axetil.
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Flurbiprofen axetil.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
3278
ChEBI
31627
ChEMBL
CHEMBL3183067

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionCatheter Related Bladder Discomfort1
4CompletedTreatmentPain1
4CompletedTreatmentPostoperative pain1
4TerminatedPreventionDelirium / Dexamethasone / Flubiprofen Axetil / Lung Cancer Non-Small Cell Cancer (NSCLC) / Surgery--Complications1
4TerminatedSupportive CareDexamethasone / Flubiprofen Axetil / General Surgery / Long-Term Effects Secondary to Cancer Therapy in Adults / Lung Cancer Non-Small Cell Cancer (NSCLC)1
Not AvailableCompletedPreventionAnaesthesia therapy / Pain1
Not AvailableCompletedSupportive CareChronic Rhinosinusitis (Diagnosis) / General Surgery1
Not AvailableCompletedTreatmentAnaesthesia therapy / General Surgery / Pain1
Not AvailableNot Yet RecruitingTreatmentC.Delivery; Surgery (Previous), Gynecological1
Not AvailableRecruitingSupportive CareAnaplasia / Postoperative pain1
Not AvailableRecruitingTreatmentAnaesthesia therapy / General Surgery / Pain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00186 mg/mLALOGPS
logP4.36ALOGPS
logP4.18ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)-6.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity87.16 m3·mol-1ChemAxon
Polarizability34.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:36 / Updated on November 02, 2019 03:28